AVTE - Aerovate Therapeutics Inc
IEX Last Trade
1.91
0.060 3.141%
Share volume: 183,704
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.85
0.06
3.24%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.21%
1 Month
6.04%
3 Months
-89.07%
6 Months
-91.64%
1 Year
-87.94%
2 Year
-90.21%
Key data
Stock price
$1.91
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.25 - $32.42
52 WEEK CHANGE
-$0.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO:
Region: US
Website: aerovatetx.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aerovatetx.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.
Recent news